Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | MTOR | P42345 | 1/20 | 0.69 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.69 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.69 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.64 |
| ▸ | ST6GAL1 | P15907 | 5/20 | 0.64 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytarabine 5'-Phosphate SCHEMBL20277485 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL14669262 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL207204 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL17934719 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL284602 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL11217191 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL16189 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL2681941 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL18785109 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL29450798 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026088303-A1 | SKIN BARRIER FUNCTION IMPROVING AGENT, CERAMIDE PRODUCTION PROMOTER, COSMETIC COMPOSITION, SKIN EXTERNAL PREPARATION, AND ORAL ADMINISTRATION PREPARATION | ヤマサ醤油株式会社 | 2026-04-30 | — | — | WO | disclosed |
| US-20250302719-A1 | COLLAGEN PRODUCTION PROMOTER, COSMETIC COMPOSITION OR EXTERNAL PREPARATION FOR SKIN, AND PREPARATION FOR ORAL ADMINISTRATION | YAMASA CORPORATION (JP) | 2025-10-02 | — | — | US | disclosed |
| US-20250041323-A1 | BDNF PRODUCTION PROMOTER | YAMASA CORPORATION (JP) | 2025-02-06 | — | — | US | disclosed |
| EP-4501405-A1 | COLLAGEN PRODUCTION PROMOTER, COSMETIC COMPOSITION OR EXTERNAL PREPARATION FOR SKIN, AND PREPARATION FOR ORAL ADMINISTRATION | YAMASA CORPORATION (JP) | 2025-02-05 | — | — | EP | disclosed |
| EP-4501333-A1 | FIBRILLIN PRODUCTION PROMOTER, COSMETIC COMPOSITION OR SKIN TOPICAL AGENT, ORALLY ADMINISTERED AGENT, AND ELASTIN FIBER PRODUCTION PROMOTER | YAMASA CORPORATION (JP) | 2025-02-05 | — | — | EP | disclosed |
| EP-4487699-A1 | BDNF PRODUCTION PROMOTER | YAMASA CORPORATION (JP) | 2025-01-08 | — | — | EP | disclosed |
| CN-119086766-A | Method for simultaneously testing 5 nucleotides and 5 nucleosides | 深圳市计量质量检测研究院 | 2024-12-06 | — | — | CN | disclosed |
| US-20240390251-A1 | SKIN CARE COMPOSITION AND USE THEREOF, AND SKIN CARE COMPOSITION RAW MATERIAL | YAMASA CORPORATION (JP) | 2024-11-28 | — | — | US | disclosed |
| CN-118853512-A | Method for producing 5' -cytidine acid in amplifying mode | 拓新药业集团股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118785819-A | BDNF production promoter | 雅玛山酱油株式会社 | 2024-10-15 | — | — | CN | disclosed |
| WO-2013019874-A9 | VITAMIN B6 DERIVATIVES OF NUCLEOTIDES, ACYCLONUCLEOTIDES AND ACYCLONUCLEOSIDE PHOSPHONATES | MBC PHARMA, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013019874-A1 | VITAMIN B6 DERIVATIVES OF NUCLEOTIDES, ACYCLONUCLEOTIDES AND ACYCLONUCLEOSIDE PHOSPHONATES | MBC PHARMA, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-24 | — | — | US | disclosed |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-24 | — | — | US | disclosed |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-24 | — | — | US | disclosed |
| US-20110098238-A1 | ELUCIDATING LIGAND-BINDING INFORMATION BASED ON PROTEIN TEMPLATES | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2277595-A2 | Compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-7553809-B2 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2009-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | P2RY2 1545/4885LMNA 4838/4885THRB 3292/4885 |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | VEGFA, FLT4, KDR | P2RY2 4179/4885LMNA 4233/4885THRB 3946/4885 |
| US-20110098238-A1 | ELUCIDATING LIGAND-BINDING INFORMATION BASED ON PROTEIN TEMPLATES | HSPBP1, HDGFL3, CACYBP | P2RY2 4564/4885LMNA 2901/4885THRB 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.